Aarey Drugs & Pharmaceuticals Intrinsic Value
Aarey Drugs & Pharmaceuticals (AAREYDRUGS) median intrinsic value is ₹38.72 from 8 valuation models (range ₹29–₹190), vs current price ₹95.19 — -59.3% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit AAREYDRUGS screener.
AAREYDRUGS Valuation Methods Summary — DCF, Graham Number & P/E
Aarey Drugs & Pharmaceuticals intrinsic value across 8 models vs current price ₹95.19 — upside/downside and value range per method. Read AAREYDRUGS dividend history for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹30.58 | ₹24.46 - ₹36.70 | -67.9% | EPS: ₹1.39, Sector P/E: 22x |
| Book Value Method | asset | ₹95.86 | ₹86.27 - ₹105.45 | +0.7% | Book Value/Share: ₹47.93, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹190.38 | ₹171.34 - ₹209.42 | +100.0% | Revenue/Share: ₹162.76, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹38.08 | ₹34.27 - ₹41.89 | -60.0% | EBITDA: ₹7.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹46.84 | ₹37.47 - ₹56.21 | -50.8% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹28.56 | ₹25.70 - ₹31.42 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹28.56 | ₹25.70 - ₹31.42 | -70.0% | Revenue Growth: -1.2%, Adj P/E: 14.9x |
| Graham Defensive Method | conservative | ₹38.72 | ₹34.85 - ₹42.59 | -59.3% | EPS: ₹1.39, BVPS: ₹47.93 |
AAREYDRUGS Intrinsic Value vs Market Price — All Valuation Models
Aarey Drugs & Pharmaceuticals fair value range ₹29–₹190 vs current market price ₹95.19 across 8 valuation models. Analyse AAREYDRUGS shareholder distribution to track promoter, FII and institutional holdings.
AAREYDRUGS Intrinsic Value Analysis — Undervalued or Overvalued?
Aarey Drugs & Pharmaceuticals median intrinsic value ₹38.72, current price ₹95.19 — Trading Above Calculated Value by 59.3%, margin of safety -100.0%.
What is the intrinsic value of AAREYDRUGS?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Aarey Drugs & Pharmaceuticals (AAREYDRUGS) is ₹38.72 (median value). With the current market price of ₹95.19, this represents a -59.3% variance from our estimated fair value.
The valuation range spans from ₹28.56 to ₹190.38, indicating ₹28.56 - ₹190.38.
Is AAREYDRUGS undervalued or overvalued?
Based on our multi-method analysis, Aarey Drugs & Pharmaceuticals (AAREYDRUGS) appears to be trading above calculated value by approximately 59.3%.
AAREYDRUGS Financial Health — Key Ratios vs Industry Benchmarks
Aarey Drugs & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 88.67 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 2.9% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.62x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
AAREYDRUGS Cash Flow Quality — Operating & Free Cash Flow
Aarey Drugs & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹10 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹-3 Cr | ₹-4 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹6 Cr | ₹5 Cr | Positive Free Cash Flow | 8/10 |